Drug intelligence / Profile preview

H101

Development stage: Unknown
Lead developer: TCRCure Biotech
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intramuscular

Overview

H101 is a neoantigen vaccine developed by TCRCure Biotech for the treatment of Diffuse Midline Glioma (DMG). The vaccine specifically targets the H3K27M mutation, a recurrent genetic alteration found in the majority of DMG cases that creates a highly specific tumor neoantigen. By presenting this mutation-derived peptide to the immune system, H101 is designed to stimulate a targeted T-cell response against glioma cells expressing the H3K27M mutation. The program is currently in Phase 1 clinical development, aiming to provide a precision immunotherapy option for this aggressive pediatric brain tumor.

Other names: H101 Neoantigen vaccineH-101 Neoantigen vaccineH 101 Neoantigen vaccine

Targets

Histone H3 lysine 27-to-methionine neoantigen

Beyond the preview

Go deeper on H101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H101.

Explore the full profile